2. Academic Validation
  3. PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis

PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis

  • J Immunol. 2017 Feb 15;198(4):1439-1451. doi: 10.4049/jimmunol.1601702.
Lindsay M Webb 1 2,  Stephanie A Amici 1,  Kyle A Jablonski 1,  Himanshu Savardekar 1,  Amanda R Panfil 3,  Linsen Li 4,  Wei Zhou 4,  Kevin Peine 5,  Vrajesh Karkhanis 6,  Eric M Bachelder 5,  Kristy M Ainslie 5,  Patrick L Green 3,  Chenglong Li 4,  Robert A Baiocchi 6,  Mireia Guerau-de-Arellano 7 8 9 10
Affiliations

Affiliations

  • 1 Division of Medical Laboratory Science, School of Health and Rehabilitation Sciences, College of Medicine, The Ohio State University, Columbus, OH 43210.
  • 2 Biomedical Sciences Graduate Program, College of Medicine, The Ohio State University, Columbus, OH 43210.
  • 3 College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210.
  • 4 Division of Medicinal Chemistry and Pharmacology, College of Pharmacy, The Ohio State University, Columbus OH 43210.
  • 5 Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599.
  • 6 Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210.
  • 7 Division of Medical Laboratory Science, School of Health and Rehabilitation Sciences, College of Medicine, The Ohio State University, Columbus, OH 43210; mireia.guerau@osumc.edu.
  • 8 Institute of Behavioral Medicine Research, College of Medicine, The Ohio State University, Columbus, OH 43210.
  • 9 Department of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Columbus, OH 43210; and.
  • 10 Department of Neuroscience, College of Medicine, The Ohio State University, Columbus, OH 43210.
PMID: 28087667 DOI: 10.4049/jimmunol.1601702
Abstract

In the autoimmune disease multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis (EAE), expansion of pathogenic, myelin-specific Th1 cell populations drives active disease; selectively targeting this process may be the basis for a new therapeutic approach. Previous studies have hinted at a role for protein arginine methylation in immune responses, including T cell-mediated autoimmunity and EAE. However, a conclusive role for the protein arginine methyltransferase (PRMT) Enzymes that catalyze these reactions has been lacking. PRMT5 is the main PRMT responsible for symmetric dimethylation of arginine residues of histones and other proteins. PRMT5 drives embryonic development and Cancer, but its role in T cells, if any, has not been investigated. In this article, we show that PRMT5 is an important modulator of CD4+ T cell expansion. PRMT5 was transiently upregulated during maximal proliferation of mouse and human memory Th cells. PRMT5 expression was regulated upstream by the NF-κB pathway, and it promoted IL-2 production and proliferation. Blocking PRMT5 with novel, highly selective small molecule PRMT5 inhibitors severely blunted memory Th expansion, with preferential suppression of Th1 cells over Th2 cells. In vivo, PRMT5 blockade efficiently suppressed recall T cell responses and reduced inflammation in delayed-type hypersensitivity and clinical disease in EAE mouse models. These data implicate PRMT5 in the regulation of adaptive memory Th cell responses and suggest that PRMT5 inhibitors may be a novel therapeutic approach for T cell-mediated inflammatory disease.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z